Doravirine
Renal Insufficiency
Thomas BenfieldSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
20 Active assets in the Renal Insufficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NORMAL HUMAN SERUM ALBUMIN Anna Cruceta | Phase 4 | BBB |
DEXAMETHASONE Augusta University | Phase 3 | BB |
Midodrine Anna Cruceta | Phase 4 | BB |
Envarsus Product University of Alberta | Phase 4 | BB |
TENOFOVIR DISOPROXIL FUMARATE Thomas Benfield | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Doravirine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →